Document is current
Any future updates will be listed below
-
Authors
Haas, Lisa
Elewaut, Anais
Gerard, Camille L. http://orcid.org/0000-0002-6007-1746
Umkehrer, Christian http://orcid.org/0000-0002-3462-2698
Leiendecker, Lukas http://orcid.org/0000-0002-6164-3953
Pedersen, Malin
Krecioch, Izabela
Hoffmann, David
Novatchkova, Maria
Kuttke, Mario http://orcid.org/0000-0003-3517-2841
Neumann, Tobias http://orcid.org/0000-0003-3908-4224
da Silva, Ines Pires
Witthock, Harriet
Cuendet, Michel A.
Carotta, Sebastian
Harrington, Kevin J. http://orcid.org/0000-0002-6014-348X
Zuber, Johannes http://orcid.org/0000-0001-8810-6835
Scolyer, Richard A. http://orcid.org/0000-0002-8991-0013
Long, Georgina V. http://orcid.org/0000-0001-8894-3545
Wilmott, James S. http://orcid.org/0000-0002-6750-5244
Michielin, Olivier
Vanharanta, Sakari http://orcid.org/0000-0001-5619-7963
Wiesner, Thomas
Obenauf, Anna C. http://orcid.org/0000-0002-9556-5914
- License Information
-
More Information
Article History
Received: 24 February 2021
Accepted: 17 May 2021
First Online: 15 July 2021
Competing interests
: O.M. received fees for advisory roles from BMS, MSD, GSK, Novartis, Roche, Pierre-Fabre and Amgen and research funding from BMS, MSD and Amgen. R.A.S received fees for professional services from Qbiotics Group Limited, Novartis Pharma AG, MSD Sharp & Dohme (Australia), NeraCare, AMGEN Inc., Bristol-Myers Squibb, Novartis Pharmaceuticals Australia Pty Limited, Myriad Genetics GmbH and GlaxoSmithKline Australia. G.V.L. is consultant adviser for Aduro Biotech Inc, Amgen Inc., Array Biopharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Evaxion Biotech A/S, Hexel AG, Highlight Therapeutics S.L., Merck Sharpe & Dohme, Novartis Pharma AG, OncoSec, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc., SkylineDX B.V. and Specialised Therapeutics Australia Pty Ltd. S.C. is an employee of Boehringer Ingelheim GmbH. J.Z. is a founder, shareholder and scientific adviser for Quantro Therapeutics GmbH. J.Z., A.C.O. and their labs received research support and funding from Boehringer Ingelheim. L.H. is currently employed as an Associate Editor of <i>Nature Cancer</i>. She was not involved in the decision-making process for the manuscript and did not have access to confidential information pertaining to peer review and editorial process. The other authors declare no conflicts of interest.
